Cited by 1,086SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesRespiratory viral infections research

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Open access

Gupta, Anil, Gonzalez-Rojas, Yaneicy, Juarez, Erick, Crespo Casal, Manuel, Moya, Jaynier, Falci, Diego R., Sarkis, Elias, Solis, Joel, Zheng, Hanzhe, Scott, Nicola, Cathcart, Andrea L., Hebner, Christy M., Sager, Jennifer, Mogalian, Erik, Tipple, Craig, Peppercorn, Amanda, Alexander, Elizabeth, Pang, Phillip S., Free, Almena, Brinson, Cynthia, Aldinger, Melissa, Shapiro, Adrienne E.·2021·New England Journal of Medicine

DOI 10.1056/nejmoa2107934

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease. METHODS: In this ongoing, multicenter, double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, nonhospitalized patients with symptomatic Covid-19 (≤5 days after the onset of symptoms) and at least one risk factor for disease progression to receive a single infusion of sotrovimab at a dose of 500 mg or placebo. The primary efficacy outcome was hospitalization (for >24 hours) for any cause or death within 29 days after randomization. RESULTS: In this prespecified interim analysis, which included an intention-to-treat population of 583 patients (291 in the sotrovimab group and 292 in the placebo group), 3 patients (1%) in the sotrovimab group, as compared with 21 patients (7%) in the placebo group, had disease progression leading to hospitalization or death (relative risk reduction, 85%; 97.24% confidence interval, 44 to 96; P = 0.002). In the placebo group, 5 patients were admitted to the intensive care unit, including 1 who died by day 29. Safety was assessed in 868 patients (430 in the sotrovimab group and 438 in the placebo group). Adverse events were reported by 17% of the patients in the sotrovimab group and 19% of those in the placebo group; serious adverse events were less common with sotrovimab than with placebo (in 2% and 6% of the patients, respectively). CONCLUSIONS: Among high-risk patients with mild-to-moderate Covid-19, sotrovimab reduced the risk of disease progression. No safety signals were identified. (Funded by Vir Biotechnology and GlaxoSmithKline; COMET-ICE ClinicalTrials.gov number, NCT04545060.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa2107934

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study
Petrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O’Donnell, L., Chernyak, Y., Tobin, K. A., Cerfolio, R. J., François, F., & Horwitz, L. I. (2020) · BMJ · doi:10.1136/bmj.m1966 · Cited by 3,045
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020
CDC COVID-19 Response Team, CDC COVID-19 Response Team, Bialek, S. R., Boundy, E. O., Bowen, V. B., Chow, N. A., Cohn, A. C., Dowling, N. F., Ellington, S., Gierke, R., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6912e2 · Cited by 2,278
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B. J., Soo, Y., Rofail, D., Im, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035002 · Cited by 1,642
Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19
Liang, W., Liang, H., Ou, L., Chen, B., Chen, A., Li, C., Li, Y., Guan, W., Sang, L., Lu, J., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.2033 · Cited by 1,387
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881

Flagged first, then by citations

Show all 25 references

Sorted by citations

Items 901–1,000 of 1,000

COVID-19: How Effective Are the Repurposed Drugs and Novel Agents in Treating the Infection?
Suet-May, C., Sin-Yee, K., Jia-Qing, L., Pey-Wen, G., Singh, H. K. A. P. R., Zhi-Zheng, T. T., Foo, J. B., Hamzah, S. B., Sellappans, R., & Yow, H.-Y. (2022) · Sudan Journal of Medical Sciences · doi:10.18502/sjms.v17i4.12550
Start-up of a high-risk COVID unit: The experience from a general hospital
Boixeda, R., Palau, A., Garcia, M., & Plensa, E. (2023) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2022.10.009
Therapeutic options in COVID-19
Horwitz, E., Perzon, O., & Mevorach, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18566-3.00034-7
Sotrovimab for the Treatment of COVID-19
Jafari, Z., & MacDougall, D. (2023) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2023.571
Currently available COVID-19 management options
Ludhiadch, A., Yadav, U. P., & Munshi, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91794-0.00001-9
Criminal Justice Issues and the COVID-19 Pandemic
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0008
Litigation and Legal Challenges to Emergency Orders
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0006
Production, Regulation, and Distribution of COVID-19 Treatments and Vaccines
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0012
Foreword
Gostin, L. O. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.002.0006
Risk, Impact, and Disadvantage
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0007
COVID-19, Law, and Regulation
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0001
About the Authors
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.002.0008
List of Abbreviations
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.002.0009
Past Legal and Regulatory Responses to Infectious Diseases
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0002
Domestic Laws and Emergency Measures
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0005
Law, Regulation, and Rights: Reflections on the COVID-19 Pandemic
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0013
Table of Legislation
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.002.0011
A Global Emergency
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0003
Table of Cases
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.002.0010
Dedication
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.002.0004
Copyright Page
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.002.0003
Civil Liability, Regulation, and Accountability
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0009
Preface and Acknowledgements
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.002.0005
COVID-19 and Workplace and Occupational Health and Safety
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0010
Development of COVID-19 Treatments and Vaccines
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0011
COVID-19 Therapeutics Can Be Safely Administered at Home
Ko, S. Q., Wong, Z., Yong, J., Ong, Y. H., & Lum, L. H.-W. (2023) · Journal of Patient Safety · doi:10.1097/pts.0000000000001101
Casiribimab/imdevimab treatment for hemodialysis patients with COVID-19 infection
Sakai, T., Yoshikawa, N., Inoue, D., Uchida, T., Kojima, T., Tomiyasu, T., Yamada, M., & Oda, T. (2023) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.56.51
Therapie von COVID-19 unter Berücksichtigung von Lebererkrankungen
Cornberg, M., & Dietz-Fricke, C. (2023) · Die Gastroenterologie · doi:10.1007/s11377-023-00681-8
The role of spike protein entry inhibitors in the treatment of mild-to-moderate covid-19 in nonhospitalized patients
Syabbalo, N. (2022) · Journal of Lung Pulmonary & Respiratory Research · doi:10.15406/jlprr.2022.09.00280
Reopening the “CANCER MOONSHOT” in the United States: A great task in the COVID-19 eraPreprint
Hu, C. (2023) · doi:10.22541/au.167844937.73607618/v1
Clinical Risk Score for Predicting Oxygen Administration Required among Patients with SARS-CoV-2 Omicron StrainsPreprint
Iwamura, N., & Tsutsumi, K. (2023) · Research Square · doi:10.21203/rs.3.rs-2618368/v1
Nano-Drug Delivery Systems for COVID-19 Drug Delivery
Parmar, K. R., & Patel, J. K. (2023) · Springer eBooks · doi:10.1007/978-3-031-20537-8_13
Effectiveness of drugs for COVID-19 inpatients in Japanese medical claim data as average treatment effects with inverse probability weighted regression adjustment: Retrospective observational studyPreprint
Mitsushima, S., Horiguchi, H., & Taniguchi, K. (2023) · medRxiv · doi:10.1101/2023.05.12.23289913
New Drugs in Synthesis Research for Viral Diseases
Ortiz, J. O., Brown, J. B., Varadhan, A. K., & Preuss, C. V. (2023) · Springer eBooks · doi:10.1007/978-3-031-20521-7_3
Monoclonal antibody for COVID-19: Unveiling the recipe of a new cocktail
Bajpai, J., Kant, S., Verma, A. K., & Pradhan, A. K. (2023) · World Journal of Respirology · doi:10.5320/wjr.v12.i1.1
Real Life Experience with Monoclonal antibody -Sotrovimab in High Risk COVID-19 Patients: A Retrospective Study in a Lebanese Tertiary Care University Hospital.Preprint
Nahhal, S. B., El-Halabi, C., Haddad, N., Zeenny, R. M., Khoury, G. S., Bizri, A. R., Kanj, S. S., & Rizk, N. (2023) · doi:10.22541/au.168517629.98516356/v1
Soluble Interleukin-2 Receptor Level in Hypertensive Patients with COVID-19-associated Pneumonia
Skakun, O., Seredyuk, N. M., Fedorov, S. V., & Вербовська, О. С. (2022) · Archive of Clinical Medicine · doi:10.21802/acm.2022.2.1
COVID-19 and Hematopoietic Stem Cell Transplantation
Oltolini, C., Greco, R., & Stanghellini, M. T. L. (2023) · Springer eBooks · doi:10.1007/978-3-031-28797-8_12
Predictors of Severe and Critical COVID-19 in Hospitalized Hypertensive Patients
Skakun, O. (2023) · Indian Journal of Respiratory Care · doi:10.5005/jp-journals-11010-1014
Retrospective View of COVID-19 Pandemic: Treatment, Management and Development of Preventive Measures
Tym, P., Bayey, E., Brittain, A., Huang, A., Nandagopal, V., Singh, A., Scarlett, C., & CY, C. B. W. (2023) · Reports on Global Health Research · doi:10.29011/2690-9480.100158
Sotrovimab Treatment for COVID-19 Effective in a B-Cell-Depleted Patient After Anti-CD20 Treatment
Murase, K., Takada, K., Arihara, Y., Miyanishi, K., & Kato, J. (2023) · Cureus · doi:10.7759/cureus.41486
Therapies that Have Shown Efficacy Against COVID-19: A Narrative Review
Regalado, L. G. C., Morales, C. N., Urbano, F., Ortegón, J. D. C., Jiménez, J. L. C., Malave, M. F. M., Balcázar-Muñoz, E. I., & Vanegas, J. S. (2023) · Salud Uninorte · doi:10.14482/sun.39.02.305.428
Estrategias de prevención y tratamiento de la infección por SARS-CoV-2 (Severe Acute Respiratory Coronavirus 2) en pacientes con enfermedad renal crónica: revisión de la literatura
Marqués, M., Múñez, E., Quiroga, B., Montejano, R., Morales, E., & Candel, F. J. (2023) · Nefrología · doi:10.1016/j.nefro.2023.10.002
Association between History of Vaccination and Symptoms at Diagnosis of Coronavirus Disease 2019
Shiraiwa, T., Takahara, M., Maeno, Y., Yamamoto, K., Shiraiwa, Y., Yoshida, Y., Nishioka, N., Kurihara, K., & Yamada, Y. (2023) · JMA Journal · doi:10.31662/jmaj.2023-0079
Tratamiento de la COVID-19, ¿qué hemos aprendido?
Rodríguez, A., Marin, M., González, P. G., Álvarez, L. S., Cobos, P. A., & Parra, J. G. (2023) · Gobierno de Navarra eBooks · doi:10.23938/spas08.0501
Analysis of vaccine responses after anti-CD20 maintenance in B-cell lymphoma in the Balearic Islands. A single reference center experience
Gutierrez, A. M., Alonso, A., García‐Recio, M., Perez, S., García-Mañó, L., Martínez-Serra, J., Ros, T., García‐Gasalla, M., Ferrer, J. M., Vögler, O., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1267485
Management of Immunosuppressed Dermatology Patients During COVID-19
Pham, J. P., & Frew, J. W. (2023) · Updates in clinical dermatology · doi:10.1007/978-3-031-45586-5_11
Randomized trial of the safety and efficacy of anti-SARS-CoV-2 mAb in the treatment of patients with nosocomial COVID-19 (CATCO-NOS)
Tremblay, A., Somayaji, R., Hoang, H. L., O’Neil, C. R., Sonpar, A., Conly, J. M., Murthy, S., Fowler, R., & Sligl, W. (2023) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2023-0008
Sotrovimab: una opción terapéutica en trasplante pulmonar
Almonacid-Sánchez, C., García-Gallo, C. L., Iribarren, M. E., Pérez, M. A., Ussetti-Gil, P., Almonacid-Sánchez, C., Hernández, R. L., & Ibáñez, S. A. (2024) · Revista de Patología Respiratoria · doi:10.24875/rpr.23000048
ФАРМАКОЛОГІЧНА ДОПОМОГА ХВОРИМ НА НЕГОСПІТАЛЬНУ ПНЕВМОНІЮ, СПРИЧИНЕНУ COVID-19
Марущак, М. І., Криса, О. В., Мялюк, О. П., Демянчук, М. Р., & Захарко, Н. В. (2023) · Health & Education · doi:10.32782/health-2023.4.19
What does it take to make progress in a disease?Preprint
Ringel, M. S., Dethier, J., Davitt, M. J., Denslow, M., Fowler, R., Hasenfuss, S. C., & Schulze, U. (2024) · medRxiv · doi:10.1101/2024.02.27.24303441
Development and validation of a prediction score for failure to casirivimab/imdevimab in hospitalized patients with COVID-19 pneumonia
Cozzi‐Lepri, A., Borghi, V., Rotundo, S., Mariani, B., Ferrari, A. M., Borgo, C. D., Bai, F., Colletti, P., Miraglia, P., Torti, C., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1293431
Oral Colchicine and Low-Dose Aspirin Combination Therapy for Non-elderly, Non-severe, Early Time From Onset, Adult Outpatients with Coronavirus Disease 2019 (COVID-19) during “The Fifth Pandemic Wave” in Japan
Inokuchi, T., HOMMA, T., Kitasato, Y., AKIYAMA, M., CHIKASUE, A., Nishii, Y., BAN, S., Adachi, T., SONEZAKI, A., Masuda, H., et al. (2023) · The Kurume Medical Journal · doi:10.2739/kurumemedj.ms7012003
Critical Care Management in Covid 19 Infection in Pregnancy
Mukherjee, B. (2024) · Acta Scientific Women s Health · doi:10.31080/aswh.2024.06.0572
Biotechnology Advances in Disease Treatment
Banesh, S., & Sevda, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99967-0.00234-9
Safety of anti-COVID treatments on the cardiovascular system
Sondh, R. S., Vankad, M., Saha, P., & Bayatpoor, Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19091-9.00011-1
The use of immunoglobulins and monoclonal antibodies against COVID-19
Popadyuk, E. E., Sizikova, T. E., Khmelev, A. L., Timofeev, M. A., Lebedev, V. N., & Borisevich, S. V. (2024) · Problems of Virology · doi:10.36233/0507-4088-225
Utility of Serum Procalcitonin and Its Clearance in Predicting Outcomes in COVID-19 Patients
Mehfooz, N., Shah, T. H., Siraj, F., Qadri, S. M., Khan, U. H., Mantoo, S., Koul, A. N., Ahmad, M., Bindroo, M. A., & Naqati, S. M. (2024) · Cureus · doi:10.7759/cureus.60203
Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial
Corado, K., Chew, K. W., Giganti, M. J., Mu, Y., Fletcher, C. V., Currier, J. S., Daar, E. S., Wohl, D. A., Li, J. Z., Moser, C., et al. (2024) · Pathogens and Immunity · doi:10.20411/pai.v9i1.660
Management of SARS-CoV-2 infection in the emergency department
del Castillo, J. M. G., Piñera, P., Jiménez, S., Losa, J. E., Berenguer, J., Moreno, S., Lima, M. V., & Putze, G. B. (2024) · Revista Española de Urgencias y Emergencias · doi:10.55633/s3me/reue.a103.2024
Vital Signs as Predictors of Oxygen Requirements in COVID-19 Outpatients: The Development of a Streamlined Risk Score
Iwamura, N., & Tsutsumi, K. (2024) · Cureus · doi:10.7759/cureus.61270
Assessment of the Efficacy and Safety of Baricitinib Treatment in COVID-19 Patients: a real-world studyPreprint
Cheng, M., Zhang, J., Xue, Z., Li, J., Pang, Z., Wang, R., Wang, L., Li, P., Kurts, C., Jia, W. P., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4418170/v1
COVID-19 – Fisiopatologia e intervenções farmacológicas: corticoides, Baricitinibe e Sotrovimabe
Veludo, A. C. D. C., Karam, J., Karam, L., & Pace, M. A. L. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n3-204
Unveiling therapeutic dynamics: An in-depth comparative analysis of neutralizing monoclonal antibodies and favipiravir in alleviating COVID-19 outpatients impacts among middle-aged and special populations (MA-FAST)
Siripongboonsitti, T., Tawinprai, K., Porntharukcharoen, T., Sirisreetreerux, S., Thongchai, T., Soonklang, K., & Mahanonda, N. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2024.102471
Drugs actively being investigated for use in COVID-19
Zhang, R., & Hung, I. F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95646-8.00016-0
Pandemi Tarihi, COVID-19 Pandemisi, Küresel ve Ulusal Mücadele Süreçleri
YILMAZ, F. (2024) · doi:10.5152/9000
EVALUATION OF THE EFFICACY OF RECIGEN AND REMDESIVIR DRUGS IN THE TREATMENT OF COVID-19 OUTPATIENTS: A COMPARATIVE STUDY IN QOM CITY, IRAN
Shajari, R., Mohammadbeigi, A., Ahmadpour, S., Shakeri, M., Adeli, S. H., Vafaeimanesh, J., Tabaraii, R., Hosseini, S. A.-S., & Asghari, A. (2024) · Studies in Medical Sciences · doi:10.61186/umj.35.3.238
USO DE ANTICORPOS MONOCLONAIS PARA TRATAMENTO DE PACIENTES COM COVID-19
Benevides, G. P., Gasco, F. B., Ghidini, E. F., Silva, I. P., Pina, M. G. D. O., Horikawa, M. J., Marques, M. F. V., Duran, L. C., Castro, A. M., Silva, L. A., et al. (2024) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2024v6n8p2175-2186
Clinical practice guideline–supported administration of monoclonal antibody therapy for high-risk patients with COVID-19: Experience of a quaternary care centre
Hammond, K., Bourdeau, F., Klein, M., Vinh, D. C., & Semret, M. (2024) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2024-0005
A Retrospective Cohort Observational Study to Assess the Efficacy of Monoclonal Antibody in Coronavirus Disease 2019 Patients
Shah, L., Tamboli, A. A., Phalgune, D. S., Badave, A., & Chendke, P. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0646
Development of an engineered ACE2 decoy for COVID-19 therapy.
Okamoto, T., Itoh, Y., & Suzuki, T. (2023) · Uirusu · doi:10.2222/jsv.73.163
Intranasal delivery of a broadly neutralizing single domain antibody targeting ACE2 protects against SARS-CoV-2 infectionPreprint
Blachier, S., Fernández, I., Conquet, L., Giraud, É., Staropoli, I., Michel, V., Szilagyi, F., Guez, S., Boucharlat, A., Chiaravalli, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.11.617877
Serum TARC Level as a Predictive Marker of Severe Disease in COVID-19 during the Omicron Variant Period of the Pandemic
Isono, T., Kojima, A., Nishida, T., Kobayashi, Y., Ishiguro, T., Takaku, Y., Kagiyama, N., & Kurashima, K. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4276-24
Critical care in outbreaks
Liu, Z., Kojan, R., & Fischer, W. A. (2024) · NUS Press eBooks · doi:10.56159/emergencies-24
Antiviral Agents
Santos, C. A. Q., & Quito, M. J. R. (2023) · ClinMicroNow · doi:10.1002/9781683674849.mcm0114
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trialPreprint
Hites, M., Massonnaud, C., Jamard, S., Goehringer, F., Danion, F., Reignier, J., Castro, N. D., Garot, D., Lapique, E. L., Lacombe, K., et al. (2024) · medRxiv · doi:10.1101/2024.02.23.24302586
SARS-CoV-2 spike protein in infectivity
Altaie, A. M., Hamdy, R., Husseiny, M. I., & Soliman, S. S. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19170-1.00015-2
Antiviral Agents
Santos, C. A. Q., & Quito, M. J. R. (2023) · ClinMicroNow · doi:10.1002/9781683670438.mcm0114
Early outpatient treatment of SARS-COV-2 infection in non-hospitalised high-risk paediatric patients in London, UK
Zsigmond, B., Trecchi, N., Ladhani, S. N., & Doerholt, K. (2025) · Journal of Infection · doi:10.1016/j.jinf.2025.106425
Real‐World Effectiveness of Sotrovimab in Patients Infected With SARS‐CoV‐2 Omicron Subvariant BA.2 in Western Sydney, Australia
Kalo, E., Basyouni, Z., Katz, G. M., Karkvandi, V., Watson, L., Crowther, H. J., Read, S. A., O'Sullivan, M. V. N., Ellis, J., Medlin, J., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70235
WITHDRAWN: SA55 broadly neutralizes SARS-CoV-2 and robustly prevents viral escape by JN.1 sublineagesPreprint
Shi, L., Bowen, A. D., Han, J., Zheng, X., Luo, H., Yao, T., Guo, M., Yu, Y., Jian, F., Cao, Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.12.638008
A Review of COVID-19 Effective Pharmaceutics Based on Molecular Targets and Single Nucleotide Polymorphisms
Seyedi, S., Seyedi, S., Gerami, M., Navid, S., Ezi, S., Nariman-Saleh-Fam, L., Nariman-Saleh-Fam, L., & Saadatian, Z. (2024) · Molecular Genetics Microbiology and Virology · doi:10.3103/s0891416824700423
Severe Acute Respiratory Syndrome Coronavirus 2 Immunology and Coronavirus Disease 2019 Clinical Outcomes
Alrubayyi, A., Huang, H., & Gaiha, G. D. (2025) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2025.02.001
Time to antiviral treatment in mild–moderate COVID-19 in the emergency department: influence of prescribing physician and effect on outcomes
Rodriguez-Leal, C., del Castillo, J. M. G., Llorens, P., Mata, D. O., Franco, B. M., Olmeda, D. M., García, E. O., Béliz, O. J. S., Frigola, A. P., Navarro, R. J. D. R., et al. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-03927-1
Navigating the COVID-19 Treatment Landscape: Efficacy and Side-Effects of Current Therapies against SARS-CoV-2
Parwani, S., Upreti, S., Mishra, C. K., Tripathi, A., Chakraborty, S., & Tiwari, S. (2025) · Current HIV Research · doi:10.2174/011570162x338375250414114957
COVID-19 Disease
Conlon, C. P., & Firth, J. D. (2020) · doi:10.1093/med/9780198746690.003.0650_update_003
Therapeutic Intervention of an Intranasally Administered Monoclonal Antibody Targeting the SARS-CoV-2 Omicron Spike Protein Against SARS-CoV-2 Omicron Infection in Mice
Kim, J., Kim, S., Kim, D., Kim, M., Baek, K., Kang, B. M., An, S., Park, I. G., Kim, S., Park, S., et al. (2025) · Viral Immunology · doi:10.1089/vim.2024.0095
Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment
Munroe, E. S., Grandits, G., Hyzy, R. C., Prescott, H. C., Barrett, T. W., Dewar, R. L., Engen, N. W., Goodman, A. L., Hatlen, T. J., Highbarger, H., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0325561
Experiences of recently diagnosed urban COVID-19 outpatients: A survey on patient worries, provider-patient interactions, and neutralizing monoclonal antibody treatment
Fish, L. E., Roberts, S. C., Bennett, T. D., Carlson, N. E., Hamer, M. K., Kwan, B. M., Russell, S., Wogu, A. F., Wynia, M. K., & Ginde, A. A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0325991
Therapeutic Implications of Melatonin and Bebtelovimab Combination for Omicron and Future Variants of Concern
Erdağ, E. (2023) · Annals of Pharmacy Practice and Pharmacotherapy · doi:10.51847/jwjmrxhjut
Rapid Discovery of Potent Neutralizing Antibodies against SARS-CoV-2 through Directed Evolution of SARS-CoV-1 Antibodies
Jung, I., Sriramulu, D. K., Yoon, J. H., Lee, J., Kim, T. W., Kweon, D., Lee, S., & Jung, S. T. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01169
CT changes in a randomized trial comparing early therapies in an outpatient population at high risk of severe COVID19 disease
Mastrorosa, I., Cozzi‐Lepri, A., Matusali, G., Colavita, F., Lanini, S., Rueca, M., Oliva, A., Berno, G., Vergori, A., Rosati, S., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-15641-1
COVID: WHO recommends two new treatments – here’s how they work
Sousa, F. (2022) · doi:10.64628/ab.accdrpgus
New anti-infective approaches to treat airway infections in persons with cystic fibrosis and bronchiectasis
Massey, J., Haidar, G., Shields, R. K., & Tyne, D. V. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001214
A Retrospective Observational Study on COVID-19 Patients Receiving Treatment with Nirmatrelvir/Ritonavir (PAXLOVID)
Murad, M. H., Atkin, S. L., Wasif, P., Behzad, A. A., Husain, A. M. J. A., d’Hellencourt, F. L., Joury, J., Aziz, M. A. A., Haridy, H., Spinardi, J., et al. (2025) · Pulmonary Therapy · doi:10.1007/s41030-025-00316-z
Assessing the Impacts of Academic and Vocational Education on Women Empowerment, A moderating Role of Culture in Southern Punjab, Pakistan
Zerish (2024) · UW Journal of Management Sciences · doi:10.56220/uwjms.v8i2.228
Viral clearance and escape during therapy of COVID-19 outpatients: A prospective cohort study
Martin‐Blondel, G., Burgat, P., Leducq, V., Porrot, F., Cottignies-Calamarte, A., Cruz, A. D., Dorival, C., Romieu, R., Chaubet, C., Cazaentre, V., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114226
Survival analysis of drug effectiveness of remdesivir and dexamethasone for confirmed COVID-19 patients using Japanese medical claim data
Mitsushima, S., Horiguchi, H., & Taniguchi, K. (2025) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2025.108268
Safety, Tolerability and Pharmacokinetics of a High-Dose, Rapid-Infusion Monoclonal Antibody: Phase I Results for Intravenous Sotrovimab 3000 mg
Sánchez‐Pearson, Y., Moore, J., Daniluk, J., Bhangu, S., Parra, S., El‐Zailik, A., Sarkar, P., Aylott, A., Moyo, F., Peppercorn, A., et al. (2025) · Drugs in R&D · doi:10.1007/s40268-025-00530-9
Self-citation
Documenting Clinical Outcomes Assessed in Outpatients with COVID-19: A Scoping Review of Randomized Controlled Trials
Kow, C. S., Ramachandram, D. S., Conway, B. R., & Hasan, S. S. (2025) · COVID · doi:10.3390/covid5120199

Authors: Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Falci, D. R., Sarkis, E., Solis, J., Zheng, H., Scott, N., Cathcart, A. L., Hebner, C. M., Sager, J., Mogalian, E., Tipple, C., Peppercorn, A., Alexander, E., Pang, P. S., Free, A., Brinson, C., Aldinger, M., & Shapiro, A. E.
Affiliations: William Osler Health System (CA)
From the Albion Finch Medical Centre, William Osler Health Centre, Toronto (A.G.); Optimus U (Y.G.-R.) and Florida International Medical Research (E.J.), Miami, Pines Care Research Center, Pembroke Pines (J.M.), and Sarkis Clinical Trials, Gainesville (E.S.) — all in Florida; Álvaro Cunqueiro Hospital, IIS Galicia Sur, Vigo, Spain (M.C.C.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (D.R.F.); Centex Studies, McAllen (J. Solis), and Central Texas Clinical Research, Austin (C.B.) — both in Texas; Vir Biotechnology, San Francisco (H.Z., A.L.C., C.M.H., J. Sager, E.M., E.A., P.S.P., M.A.); GlaxoSmithKline, Stevenage, United Kingdom (N.S., C.T.); GlaxoSmithKline, Cambridge, MA (A.P.); Pinnacle Research Group, Anniston, AL (A.F.); and the Departments of Global Health and Medicine, University of Washington, and Fred Hutchinson Cancer Research Center, Seattle (A.E.S.).
Hospital de Clínicas de Porto Alegre (BR)
The University of Texas at Austin (US)
VIR Biotechnology (United States) (US)
GlaxoSmithKline (United Kingdom) (GB)
GlaxoSmithKline (United States) (US)
University of Washington (US)
Corresponding author: Shapiro, Adrienne E.
ORCID: Pang, Phillip S.
Shapiro, Adrienne E.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2021-11-18
Volume: 385
Issue: 21
Pages: 1941-1950
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2107934
OpenAlex: W3208080692
Cited by: 1,086
References: 25
Citations by year: 2026: 25 · 2025: 72 · 2024: 119 · 2023: 294 · 2022: 509 · 2021: 62
FWCI: 78.13
Type: journal article
Language: en
Open access: green
doi.org
Licence: cc-by-nc-nd
www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
medRxiv (acceptedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: Vir Biotechnology, Inc., in collaboration with GlaxoSmithKline
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Keywords: sotrovimab, COVID-19 pandemic, SARS-CoV-2, neutralizing monoclonal antibodies, early treatment, disease progression, hospitalization, mortality, high-risk patients, non-hospitalized patients, presymptomatic treatment, adverse events
MeSH terms: SARS-CoV-2, COVID-19 Drug Treatment, Adult, Aged, Ambulatory Care, Double-Blind Method, Female, Hospitalization, Humans, Infusions, Intravenous, Length of Stay, Male, Middle Aged, Incidence, Disease Progression, Antibodies, Neutralizing, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks